FRANKFURT (dpa-AFX) - Following an encouraging analyst report, demand for Evotec shares soared on Tuesday. Investors responded to a buy recommendation issued by Berenberg analyst Christian Ehmann in his initial coverage of the stock.
During the course of the morning, the shares expanded their gains significantly, rising by more than ten percent. This marked the start of an upward trend for the 2026 trading year, following recent setbacks. After two consecutive days of corrections, the stock's year-to-date gain rebounded to nearly 20 percent.
In his report, analyst Ehmann argued that Evotec sits precisely at the intersection of growing outsourcing needs among pharmaceutical companies and the drive for cost-efficient research. He noted that the stock's valuation leaves ample room for growth, even if demand merely normalizes. According to Ehmann, the market currently attributes only limited value to Evotec's long-term partnerships, expertise in biologics, and potential portfolio adjustments. He set a price target of 10 euros, implying more than 50 percent upside potential for the shares./tih/jha/
